



Become a co-owner of MedTech technologies

2024


About the company



MedTech is one of the main global trends.

\$ 175 billion

Analytical resources project the global MedTech market volume to reach \$ 175 billion by 2025.



MLC, a company incorporated in the UAE, is engaged in creating and developing its own original CGM system (Continuous Glucose Monitoring) and launching it on the international market.

The CGM system helps people **measure blood glucose levels more accurately and prolong life** through quality monitoring without the need for frequent finger pricking compared to standard glucose meters.



Advantages of CGM



CGM is a cutting-edge technology that provides **real-time** tracking of blood glucose levels.

Forget test strips – with CGM you are always aware of your vitals, 24/7.



There is **no age restriction** for using CGM systems.



Advantages of CGM

- ✓ Accuracy: Accurate and reliable real-time glucose level measurements.
- ✓ Comfort: Forget about frequent pricking (non-invasive application) – the CGM sensor is fitted on the body and works for a set period of time.
- ✓ Control: Alert on critical changes in blood glucose levels.

MLC's first product



The flagship product of the MLC project is CGM Fly

It consists of the sensor installer and the sensor itself, which is fitted to the forearm.



MLC's first product



Data from the sensor is transmitted to a mobile app that continuously monitors and alerts you when critical changes in blood glucose levels occur.

The system works for **14 days**, then it must be replaced with a new one.



When using a CGM system, glucose level data is available in real time.

This allows you to respond to changes instantly and take the necessary steps to maintain optimal glucose levels.

Using CGM systems helps to improve the quality and length of life.


Progress now



TECHNOLOGIES ALREADY EXIST

A number of research institutes and teams in Russia [are working on researching the technology we need.](#)


These teams work on a commercial basis and offer us their solutions.



FAST IMPLEMENTATION

When selecting a technology, we focus on the [ability to quickly implement the already existing technologies.](#)

We have already selected many technology options suitable for our CGM.



EXPERIENCE ACCUMULATED OVER YEARS

We work with teams that have spent many years studying scientific achievements, conducting their own research and publishing it. There was no emphasis on practical application of the created technologies.

This has created a [huge pool of knowledge and ready-to-use technologies that are fit for implementation.](#)



DOING RESEARCH AND DEVELOPMENT (R&D)

[Using off-the-shelf technologies implies their mandatory adaptation](#) to our task. Adaptation requires accurate scientific work, which is referred to in the scientific community as research and development (R&D).

The selected research teams are carrying out work on our research and development plan (R&D) right now.

Work is being done in different areas at the same time and new ones are being added.

There are a total of 7 areas, which feature a line-up of more than 20 other areas.

[The main focus is given to the biosensor](#) and the technology to produce it.

Future progress



PROTOTYPE

We will complete the first prototype **in 2025**.

A prototype is a fully functional device with a ready-made design and technology incorporated into it.




RESEARCH AND DEVELOPMENT (R&D) RESULT

Every completed research and development (R&D) project is accompanied by know-how and **can be protected against copying by patents**.

Patents in our field are not business-critical, but are necessary for the final assessment of the technology's value and capitalisation.

At the current stage, most of the work is being done in the field of biotechnology, which is very difficult to replicate. There is also a continuous improvement in the baseline for these activities.

Upon completion of all work, we will apply for copyright protection with **at least 10 patents** to be obtained.



FROM PROTOTYPE TO PRODUCTION

The next step after the prototype is to fine-tune the production cycle to scale up and increase production.

Our advantages at this stage are that **there is no need for large production facilities**.

The main value of the production is the equipment and organisation of clean premises.



Financial growth prospects for CGM Fly

Dexcom[®]
CONTINUOUS GLUCOSE MONITORING

\$ 3,403 billion

+21,85%

DexCom's revenue for the twelve months ended September 30, 2023 was \$ 3.403 billion, representing an increase of 21.85% compared to the previous year.

According to statistics from publicly available analytical data.

\$ 3,62 billion

+24%

In fiscal 2023, total preliminary unaudited revenue will be approximately \$ 3.62 billion, **an increase of 24%** over 2022.

The forecast for 2024 shows the growth of **about 21%** compared to 2023.

30%




The number of consumers is increasing annually.

The multi-billion dollar revenue generated shows a steady **increase of up to 30% per year.**

The consumption growth is not compatible with the supply in the global CGM device market.

Financial growth prospects for CGM Fly



The number of people with diagnosed diabetes is projected to rise to 643 million by 2030 and to 783 million by 2045.



Together with the increasing popularity of the innovative CGM system, a **steady increase in sales is being driven**.

Promotion in the global market will increase the availability of the system to a wide range of consumers.

643 million

783 million

2030



2045

First target figures:

500,000
users

12 million
units sold

from 2025 to 2027
and further growth

How do you become a co-owner of the technology?




MLC is now attracting funding to create its own technology.

All technologies developed are included in the company's intellectual property and capitalise it.




There is a licence fee built into every item produced. It does not matter who the manufacturer is, whether it is a private, joint or licensed production.

Each item sold generates revenue for the investors of the technology.




Register
in the personal office

my.mlc.health




2

Fill in
the profile data



3

Add funds to the internal account
and select an investment package



4

After purchasing an investment package, the **shares will be displayed immediately in the personal office.**



Upon investment, you get the investment shares, which are credited immediately after the purchase electronically and displayed in the personal office.

An investment agreement is entered into with each investor on the company's platform my.MLC.health You can formalise the ownership of your shares by drawing up a certificate for them.

The cost growth from stage to stage can increase by **up to 100 times**



The price of the shares purchased at the current stage 6 will increase by **up to 400%** before the funding is completed, according to the marketing plan

Dividends



50%

Of the technology's profitability will be **distributed for dividend payments.**



~100% per annum

The dividends may amount to ~100% per annum in case of purchasing a package of shares at the price of stage 6

This indicator depends on the amount of sales and may increase with their growth.



in **2025-2026**

Dividend payments will start after the sales launch in 2025-2026

Based on meeting the financial targets in accordance with the roadmap.

Capitalisation

1 share = \$ 1

Our goal



Capitalisation is market driven and we can be guided by the performance of existing companies.



1 customer in this area is estimated by the market to be worth approximately \$ 10,000 in capitalisation.



With 100 thousand customers, capitalisation could be \$ 1 billion, which is 1 share = \$ 0.05.

With 2 million customers, capitalisation could be \$ 20 billion, which is 1 share = \$ 1



MLC Fly project funding stages



17 funding stages
are divided into 3 project
implementation phases

The phases determine
the level of project implementation
and the involvement of major
investment funds in funding the
project.

The stages determine
the fulfillment of financial targets,
upon achieving which the price of
shares changes.



Pre-Seed Phase

Funding stage 1-7

2024

Net funding required (fundraising costs not included): \$ 2 million.

Distribution:
15% of the company's shares.

Main phase value:
Creating in-house prototype, certification,
technology refinement.

Source of funding:
small and medium sized private investments
from around the world. Business angels,
venture capital funds and accelerators with a
focus on the Pre-Seed phase.

MLC Fly project funding stages

Seed phase

Funding stages 8-12

2025

Net funding required:
\$ 5 million.

Distribution:
18% of the company's shares.

Main phase value:
Creating a minimal production line and certification in one country. Launch of the first batch for sale.

Source of funding:
major investors, venture capital funds, as well as private small investments by individuals around the world.

Scaling phase (Round A)

Stages 13-17

2025 - 2027

Net funding required:
\$ 20 million.

Distribution:
15% of the company's shares.

Source of funding:
large investors, venture capital funds, private small investments by individuals around the world.

Main phase value:
Expanding sales geography and building supply chains to other countries. Scaling up and growth start.

Reaching 500,000 users and 12 million sales units and further growth.

Public Markets IPO

2030

Net funding attracted:
from \$ 500 million.

Source of funding: professional stock market.

- ✓ Growth and expansion.
- ✓ Creating a network of branches.
- ✓ International expansion.




Legal framework



Our project has a group of companies in several jurisdictions to organise its activities:

Saint Lucia, UAE, Russia.



Registered office address:

The Meydan Hotel, Grandstand, 6th floor, Meydan Nad Al Sheba, Dubai, U.A.E



Investing in health is an investment in the future and the basis for financial independence in the present.

This presentation does not form part of an agreement or offer with the company. The calculations given in the presentation are tentative and subject to change.

